- Home
- EAT vs RYTM Comparison
EAT vs RYTM Comparison
Compare EAT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAT
- RYTM
- Stock Information
- Founded
- EAT 1975
- RYTM 2008
- Country
- EAT United States
- RYTM United States
- Employees
- EAT N/A
- RYTM N/A
- Industry
- EAT Restaurants
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- EAT Consumer Discretionary
- RYTM Health Care
- Exchange
- EAT Nasdaq
- RYTM Nasdaq
- Market Cap
- EAT 3.2B
- RYTM 3.1B
- IPO Year
- EAT N/A
- RYTM 2017
- Fundamental
- Price
- EAT $130.89
- RYTM $56.14
- Analyst Decision
- EAT Hold
- RYTM Strong Buy
- Analyst Count
- EAT 20
- RYTM 10
- Target Price
- EAT $91.24
- RYTM $63.70
- AVG Volume (30 Days)
- EAT 982.5K
- RYTM 470.5K
- Earning Date
- EAT 01-29-2025
- RYTM 11-05-2024
- Dividend Yield
- EAT N/A
- RYTM N/A
- EPS Growth
- EAT 31.88
- RYTM N/A
- EPS
- EAT 4.07
- RYTM N/A
- Revenue
- EAT $4,541,600,000.00
- RYTM $112,530,000.00
- Revenue This Year
- EAT $8.81
- RYTM $63.64
- Revenue Next Year
- EAT $3.68
- RYTM $42.98
- P/E Ratio
- EAT $32.85
- RYTM N/A
- Revenue Growth
- EAT 8.39
- RYTM 81.55
- 52 Week Low
- EAT $37.25
- RYTM $35.17
- 52 Week High
- EAT $133.82
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- EAT 61.08
- RYTM 45.40
- Support Level
- EAT $126.39
- RYTM $54.52
- Resistance Level
- EAT $131.79
- RYTM $58.56
- Average True Range (ATR)
- EAT 4.07
- RYTM 1.90
- MACD
- EAT -0.86
- RYTM -0.65
- Stochastic Oscillator
- EAT 72.78
- RYTM 21.10
About EAT Brinker International Inc.
Brinker International Inc operates casual dining restaurants under the brand's Chili Grill and Bar (Chili's) and Maggiano's Little Italy (Maggiano's). Chili's falls in the Bar and Grill category of casual dining. Its menu features Fresh Mex and Fresh Tex favorites including signature items such as slow-smoked baby back ribs, craft burgers, fajitas, and bottomless chips and salsa paired with tableside guacamole. Maggiano's is an Italian restaurant brand with a full lunch and dinner menu offering chef-prepared, such as appetizers, chicken, seafood, veal and prime steaks, and desserts. The company generates maximum revenue from Chili's segment.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.